MOTS-c: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 7 sources cited
Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondrial-derived peptide that functions as a systemic exercise mimetic and metabolic regulator. Discovered in 2015 by Dr. Changhan David Lee's lab at USC, it is the first peptide shown to be encoded in the mitochondrial genome yet act on the nuclear genome, fundamentally challenging the traditional view of mitochondria as passive energy producers. MOTS-c activates AMPK, regulates metabolic homeostasis, and has demonstrated remarkable anti-aging and exercise-mimetic effects in both preclinical and early human studies.
Mechanism of Action
MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded within the 12S rRNA gene of mitochondrial DNA. It represents a paradigm shift in cell biology: a mitochondrial-encoded peptide that translocates to the nucleus during metabolic stress to directly regulate nuclear gene expression — a process now called 'mitonuclear communication.' The primary mechanism begins with MOTS-c's inhibition of the folate-methionine cycle in the cytoplasm, specifically by disrupting the de novo purine biosynthesis pathway. This creates a transient metabolic stress signal that activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation cascades into multiple downstream effects: increased glucose uptake via GLUT4 translocation to the cell membrane, enhanced fatty acid oxidation through ACC (acetyl-CoA carboxylase) inhibition, and stimulation of mitochondrial biogenesis through PGC-1α upregulation. What makes MOTS-c unique among metabolic peptides is its nuclear translocation. During metabolic stress (exercise, caloric restriction, or exogenous MOTS-c administration), the peptide physically enters the nucleus and interacts with antioxidant response element (ARE) promoters, upregulating a suite of protective genes including those regulated by Nrf2 — the master transcription factor for cellular stress defense. This includes increased expression of glutathione synthesis enzymes, heme oxygenase-1 (HO-1), and NAD(P)H quinone oxidoreductase 1 (NQO1). Exercise raises MOTS-c in human muscle and blood. A 2015 commentary suggested the Northeast Asian m.1382A>C variant in the MOTS-c sequence might contribute to Japanese longevity, but the large cohort analysis of that variant found men carrying it had more type 2 diabetes, and the variant peptide was less insulin-sensitizing. The peptide also regulates insulin sensitivity independently of insulin signaling — MOTS-c-treated mice were protected from diet-induced insulin resistance and obesity on a high-fat diet, with skeletal muscle as the peptide's main target organ. Beyond metabolism, MOTS-c has demonstrated immunomodulatory effects. It regulates T-cell homeostasis, modulates inflammatory cytokine production, and has shown protective effects against inflammatory conditions in preclinical models. Recent research also indicates MOTS-c improves physical performance: in a 2021 study, mice treated with MOTS-c showed significantly improved running endurance and resistance to age-related physical decline.
MOTS-c Benefits: What the Research Shows
- Lee et al. (2015) in Cell Metabolism published the landmark discovery of MOTS-c, demonstrating it prevented age-dependent and high-fat-diet-induced insulin resistance in mice and activated AMPK in skeletal muscle
- A 2015 commentary in Aging Cell proposed that the Northeast Asian m.1382A>C variant in the MOTS-c sequence might help explain Japanese longevity. A later analysis of 27,527 people found the opposite for metabolic health: men carrying the C-allele had more type 2 diabetes, and the altered peptide was less insulin-sensitizing
- Kim et al. (2018) in Cell Metabolism demonstrated that MOTS-c translocates to the nucleus during metabolic stress in an AMPK-dependent way and regulates nuclear genes, including antioxidant response element genes, interacting with stress transcription factors such as NRF2
- Reynolds et al. (2021) in Nature Communications showed MOTS-c enhanced physical performance in young, middle-aged and old mice, and that treatment started in late life increased physical capacity and healthspan
- In humans, exercise induces endogenous MOTS-c expression in skeletal muscle and in the circulation, which is how the peptide came to be described as exercise-induced
- Research in Cell Reports (2021) showed MOTS-c acts on T cells through T cell receptor and mTORC1 signalling, reducing islet-infiltrating immune cells and preventing autoimmune beta cell destruction in NOD mice; serum MOTS-c was lower in people with type 1 diabetes than in healthy controls
- The first registered trial of MOTS-c in people began recruiting in 2026: a phase 2, placebo-controlled study of subcutaneous MOTS-c in 120 adults with prediabetes and overweight or obesity. No results have been published
MOTS-c Dosage
- Standard research dose: 5 mg subcutaneous injection, 3–5 times per week
- Loading protocol: 5 mg daily for 2 weeks, then transition to 5 mg every other day
- Some protocols use 10 mg 2–3 times per week as an alternative to daily lower doses
- Optimal timing: administer in the morning or pre-exercise to align with natural metabolic activity
- Cycle: 8–12 weeks on, 4 weeks off, though some longevity protocols use continuous low-dose administration
- Can be combined with fasted-state exercise for synergistic AMPK activation
- For metabolic support: 5 mg 3x/week is the most common maintenance protocol
- Inject subcutaneously in the abdomen or thigh; rotate injection sites
- Start with 5 mg every other day for the first week to assess tolerance before increasing frequency
- No specific food timing required, though some practitioners recommend fasted administration
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
MOTS-c Side Effects & Safety
Known Side Effects
- Injection site reactions — mild redness or soreness at the subcutaneous injection site, typically resolving within hours
- Transient hypoglycemia — possible in individuals who are fasted or on glucose-lowering medications due to MOTS-c's insulin-sensitizing effects; monitor blood glucose if diabetic
- Mild fatigue — some users report temporary tiredness in the first 1–2 days, potentially reflecting metabolic adjustment
- Gastrointestinal discomfort — infrequently reported, generally mild nausea or abdominal discomfort
- Headache — occasional, usually during the first week of use and self-resolving
- Muscle soreness — some users report mild myalgia similar to post-exercise soreness, consistent with AMPK activation in skeletal muscle
Safety Profile
MOTS-c is an endogenous peptide naturally produced by human mitochondria, which provides a favorable baseline safety profile. No toxicology study of MOTS-c has been published, so claims about organ toxicity or carcinogenicity cannot be made in either direction; the animal work reports metabolic and performance outcomes rather than safety endpoints. The primary theoretical concern is hypoglycemia in individuals taking insulin or sulfonylureas, as MOTS-c independently enhances glucose uptake in skeletal muscle. Diabetic individuals should monitor blood glucose closely and coordinate with their physician. Drug interactions have not been studied, and immunogenicity has not been measured in people. Human testing is only beginning: the first registered trial, a phase 2 study in prediabetes, started recruiting in 2026. However, long-term human safety data from controlled trials is still limited, and the peptide remains in early-phase clinical investigation. The quality of sourced material matters significantly — only use third-party tested product from reputable suppliers. Pregnant and breastfeeding individuals should avoid use due to lack of safety data.
What to Expect
Week 1: Subtle improvements in energy and exercise recovery may be noticed. Some users report feeling slightly more energized during workouts. Mild injection site soreness is possible. Blood glucose may trend slightly lower if monitored. Weeks 2–3: More noticeable improvements in exercise capacity and endurance. Users commonly report being able to sustain cardio longer and recover faster between sessions. Fasting glucose and metabolic markers begin to improve measurably. Appetite regulation normalizes — fewer cravings, more stable energy between meals. Weeks 4–6: Peak metabolic effects become apparent. Body composition changes are visible — reduced abdominal fat, improved muscle definition, especially when combined with exercise and proper nutrition. Insulin sensitivity improvements are significant and measurable with bloodwork. Energy levels are notably higher and more stable throughout the day. Weeks 8–12: Cumulative benefits are well-established. Bloodwork typically shows improved fasting glucose, HbA1c trending downward, and lipid panel improvements. The exercise-mimetic effects are most pronounced in combination with actual exercise. What happens after stopping has not been studied in people, so how long any benefit lasts is unknown.
Common Stacks
NAD+
NAD+ supplementation provides the substrate fuel that MOTS-c helps the mitochondria utilize more efficiently, creating synergistic metabolic enhancement
SS-31 (Elamipretide)
SS-31 stabilizes cardiolipin in the mitochondrial inner membrane while MOTS-c activates AMPK and mitochondrial biogenesis — complementary mitochondrial optimization
5-Amino-1MQ
5-Amino-1MQ inhibits NNMT to raise NAD+ and promote fat metabolism, synergizing with MOTS-c's AMPK activation for enhanced metabolic and body composition benefits
Epitalon
Epitalon activates telomerase for longevity support while MOTS-c addresses the metabolic axis of aging, covering complementary hallmarks of aging
Storage & Handling
Store lyophilized MOTS-c at -20°C for long-term storage (up to 24 months). Refrigerated storage at 2–8°C is acceptable for up to 6 months. Reconstitute with bacteriostatic water — typically 1–2 mL per 5 mg vial. After reconstitution, store refrigerated at 2–8°C and use within 4 weeks. Do not freeze reconstituted solution. MOTS-c is a relatively short peptide (16 amino acids) and is moderately stable, but should be protected from heat, light, and repeated freeze-thaw cycles.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015.
- Kim KH, Son JM, Benayoun BA, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021.
- Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021.
- Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015.
- Kong BS, Min SH, Lee C, et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep. 2021.
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). ClinicalTrials.gov. 2026.
Related Peptides
Track MOTS-c in Your Protocol
Log your MOTS-c doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free